HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Remels, A. H. Articles by Schols, A. M. Search for Related Content PubMed PubMed Citation Articles by Remels, A. H. Articles by Schols, A. M.

Peroxisome proliferator-activated receptors: a therapeutic target in COPD?

¹ Depts of Respiratory Medicine, and ² Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, University of Maastricht, Maastricht, the Netherlands.

CORRESPONDENCE: A. H. Remels, Dept of Respiratory Medicine, University of Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands. Fax: 31 433875051. E-mail: a.remels{at}pul.unimaas.nl

Keywords: Chronic obstructive pulmonary disease, inflammation, oxidative stress, peroxisome proliferator-activated receptors, skeletal muscle

Received: June 8, 2007
Accepted November 4, 2007

Extrapulmonary pathology significantly impairs clinical outcome in chronic obstructive pulmonary disease (COPD).

The peroxisome proliferator-activated receptors (PPARs) are implicated in the regulation of several hallmarks of systemic COPD pathology, including cachexia, decreased oxidative muscle metabolism, oxidative stress and systemic inflammation.

Recently, expression of PPARs and related cofactors was shown to be reduced in peripheral skeletal muscle of patients with moderate-to-severe COPD and muscle weakness.

The current authors hypothesise that impaired peroxisome proliferator-activated receptor signalling may underlie some of the muscular disturbances in chronic obstructive pulmonary disease. Proposed mechanisms will be outlined in the present article, as well as the therapeutic potential of peroxisome proliferator-activated receptor modulation in the treatment of skeletal muscle dysfunction.

This article has been cited by other articles:

				P. J. Barnes and B. R. Celli Systemic manifestations and comorbidities of COPD Eur. Respir. J., May 1, 2009; 33(5): 1165 - 1185. [Abstract] [Full Text] [PDF]

				P. J. Barnes Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities Proceedings of the ATS, December 1, 2008; 5(8): 857 - 864. [Abstract] [Full Text] [PDF]